The multi-year collaboration agreement is intended to discover and develop chimeric antigen receptor (CAR) T-cell therapies and armouring technologies for up to three oncology targets
An image of Roswell Park Cancer Institute in New York, US. (Credit: Andre Carrotflower from Wikimedia Commons)
Generate:Biomedicines and Roswell Park Comprehensive Cancer Center have partnered to expedite the development of new cell therapies for oncology using generative artificial intelligence (AI).
The multi-year collaboration agreement is intended to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armouring technologies.
Both firms will develop these technologies for up to three oncology targets, including ovarian cancer and other solid tumours.
As per the terms of their partnership, Generate:Biomedicines and Roswell Park will work together to develop optimal cell treatments, which entail modifying a patient’s T cells to identify and eliminate malignancies.
The partnership combines The Generate Platform’s programmability and scalability with Roswell Park’s experience in cell therapy design, clinical development, and manufacturing to offer superior cell therapies for patients.
The Generate Platform is a machine learning-powered generative biology platform.
Generate:Biomedicines, which raised $273m in September this year, has designed the platform to increase the speed at which targets and therapeutics are identified and validated.
Generate:Biomedicines research & development executive vice president Alex Snyder said: “This is a powerful combination that brings together Roswell Park’s world-leading expertise in cell therapy manufacturing and our technology and computational power.”
Additionally, both firms have agreed to split the costs of research and development as well as any profits made from the commercialisation of joint venture products.
For phase 1 and 2 clinical trials, Roswell Park is expected to act as a site and suggest lead investigators.
The cancer centre has recently announced the expansion of its Current Good Manufacturing Practice (cGMP) facilities with support from the New York State funds.
Roswell Park Comprehensive Cancer Center deputy director and chair of medicine Renier Brentjens said: “This collaboration with Generate:Biomedicines will allow us to harness the power of generative AI to rapidly advance our research to make groundbreaking cancer therapies for patients who are in need of new treatment options.”